company background image
PXS

PharmaxisASX:PXS Stock Report

Last Price

AU$0.11

Market Cap

AU$57.7m

7D

0%

1Y

18.3%

Updated

20 Jan, 2022

Data

Company Financials
PXS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

PXS Stock Overview

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Pharmaxis
Historical stock prices
Current Share PriceAU$0.11
52 Week HighAU$0.15
52 Week LowAU$0.071
Beta0.58
1 Month Change0%
3 Month Change-4.35%
1 Year Change18.28%
3 Year Change-56.86%
5 Year Change-60.00%
Change since IPO-75.56%

Recent News & Updates

Oct 27
Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

In the past three years, the share price of Pharmaxis Ltd ( ASX:PXS ) has struggled to grow and now shareholders are...

Shareholder Returns

PXSAU PharmaceuticalsAU Market
7D0%-2.5%-1.7%
1Y18.3%-12.9%7.7%

Return vs Industry: PXS exceeded the Australian Pharmaceuticals industry which returned -12.9% over the past year.

Return vs Market: PXS exceeded the Australian Market which returned 7.7% over the past year.

Price Volatility

Is PXS's price volatile compared to industry and market?
PXS volatility
PXS Average Weekly Movement9.4%
Pharmaceuticals Industry Average Movement8.3%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.3%
10% least volatile stocks in AU Market3.6%

Stable Share Price: PXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PXS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199863Gary Phillipshttps://www.pharmaxis.com.au

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma.

Pharmaxis Fundamentals Summary

How do Pharmaxis's earnings and revenue compare to its market cap?
PXS fundamental statistics
Market CapAU$57.67m
Earnings (TTM)-AU$1.17m
Revenue (TTM)AU$28.29m

2.0x

P/S Ratio

-49.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PXS income statement (TTM)
RevenueAU$28.29m
Cost of RevenueAU$7.84m
Gross ProfitAU$20.44m
ExpensesAU$21.61m
Earnings-AU$1.17m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Jan 31, 2022

Earnings per share (EPS)-0.0022
Gross Margin72.28%
Net Profit Margin-4.13%
Debt/Equity Ratio0%

How did PXS perform over the long term?

See historical performance and comparison

Valuation

Is Pharmaxis undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PXS (A$0.11) is trading below our estimate of fair value (A$1.39)

Significantly Below Fair Value: PXS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PXS is unprofitable, so we can't compare its PE Ratio to the Global Pharmaceuticals industry average.

PE vs Market: PXS is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PXS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PXS has negative assets, so we can't compare its PB Ratio to the AU Pharmaceuticals industry average.


Future Growth

How is Pharmaxis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

75.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmaxis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Pharmaxis performed over the past 5 years?

5.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PXS is currently unprofitable.

Growing Profit Margin: PXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PXS is unprofitable, but has reduced losses over the past 5 years at a rate of 5.9% per year.

Accelerating Growth: Unable to compare PXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PXS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.2%).


Return on Equity

High ROE: PXS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Pharmaxis's financial position?


Financial Position Analysis

Short Term Liabilities: PXS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PXS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PXS is debt free.

Reducing Debt: PXS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable PXS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: PXS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 18.9% per year.


Dividend

What is Pharmaxis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PXS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.1yrs

Average management tenure


CEO

Gary Phillips (60 yo)

8.83yrs

Tenure

AU$682,640

Compensation

Mr. Gary Jonathan Phillips, BPharm, MBA has been Chief Executive Officer and Managing Director of Pharmaxis Ltd. since March 12, 2013 and served as its Chief Operating Officer from November 2003 to March 2...


CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD492.92K) is above average for companies of similar size in the Australian market ($USD290.00K).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PXS's management team is seasoned and experienced (9.1 years average tenure).


Board Members

Experienced Board: PXS's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PXS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32%.


Top Shareholders

Company Information

Pharmaxis Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Pharmaxis Ltd
  • Ticker: PXS
  • Exchange: ASX
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$57.673m
  • Shares outstanding: 524.30m
  • Website: https://www.pharmaxis.com.au

Number of Employees


Location

  • Pharmaxis Ltd
  • 20 Rodborough Road
  • Frenchs Forest
  • New South Wales
  • 2086
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/20 15:52
End of Day Share Price2022/01/20 00:00
Earnings2021/09/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.